Hepatitis C Treatment Checklists

| Prior to Treatment | |
|---|--|
| Immediately prior: | Pregnancy test (if applicable) |
| | Uric Acid (only if ribavirin to be given) |
| Acceptable within | CBC (without diff) |
| 3 months: | HBV DNA (if HBcAb+) ¹ |
| | HCV RNA |
| | Hepatic Function Panel and eGFR ² |
| | PT/INR |
| Acceptable within | |
| 6 months: | AFP |
| Acceptable within | Serum fibrosis test (FibroTest-Quest or Fibrosure-LabCorp) |
| 1 year: | or FibroScan |
| | Vitamin D 25OH (consider and treat if deficient) |
| | Genotype (not necessary with pangenotypic treatments; however, consider |
| | if patient has cirrhosis, past treatment failure or concern for reinfections) |
| | HIV screening |
| | A1C or Fasting Glucose |
| | |
| Once: | Hepatitis B core antibody & surface antigen |
| | NS5a RAS (If failed prior DAA treatment or if cirrhotic genotype 3 & treating |
| | with Epclusa) |
| Miscellaneous: | (15 1 1 1 1 1 1 1 1 1 1 1 1 1 2) |
| | vaccine status (If unknown: draw HAV antibody total IgG) |
| | vaccine status (If unknown: draw HBsAg & HBsAb) |
| | g-drug interactions |
| PHQ-9 base | eine |
| AUDIT-C | and an arrange of the contract |
| | out pregnancy prevention (ethinyl estradiol not recommended with Mavyret) |
| | ign Treatment Readiness Attestation |
| Review me | dication-specific Information Packet at Treatment Start |
| Monitoring During Trea | atment |
| | in, see footnote ³ below. |
| ~ | nts taking diabetes meds to monitor for hypoglycemia |
| | |
| - | ts taking warfarin of potential need to change dose and monitor INR for |
| · | cic anticoagulation |
| Week 4 | |
| HCV RNA (consider LFTs (as clinically in | if concern for medication adherence) |
| Pregnancy test | uicateuj |
| HBV DNA ¹ | |
| | |

Weeks 8, 12, 16, 20, & 24 (as clinically indicated)

- 1- Hep B: If cAb+ & HBV DNA detected pre-treatment **OR** if Hep B carrier (sAg+) **OR** seroconverted carrier, check HBV DNA monthly during treatment & 3 months after treatment. If HBV DNA negative pre-treatment & not a carrier, check again only at end of treatment
- 2- Child-Pugh Calculator: https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp
 If score >6 (Child-Pugh B or C), do not treat with Mavyret™, Zepatier™, or Vosevi® and consult Liver Disease Specialist.
- 3- If treatment includes ribavirin, additional monitoring of CBC, CMP is recommended at weeks 2, 4 and monthly throughout treatment and adjustment to ribavirin dose if GFR <50 or anemic. Consult Liver Disease specialist if patient is prescribed ribavirin.

Hepatitis C Treatment Checklists

| LFTs (as | clinically indicated) |
|----------|-----------------------|
| Pregnand | cy test |
| HBV DNA | \ ¹ |

Monitoring After Treatment:

12 weeks after last dose:

- HCV RNA (to test for cure)
- AFP (if advanced fibrosis or cirrhosis and more than 6 months since last result)
- HBV DNA¹

6 months post-treatment:

• If Advanced Fibrosis or Cirrhosis prior to treatment continue AFP & RUQ q 6 months to screen for hepatocellular carcinoma (HCC)

1 year post-treatment:

- Zero to minimal scarring (F0-F2): yearly CBC & LFTs as clinically indicated
- Advanced Fibrosis (F3): RUQ US & AFP q 6 months; yearly CBC, LFTs, & AFPs
 - Liver Field Clinic appointment and FibroScan every 2 years. FibroScan to be done in Field Clinic.
- Cirrhosis (F4): RUQ US & AFP g 6 months; yearly CBC, CMP, AFP, PT/INR
 - Yearly Liver Field Clinic appointment. FibroScan to be done at discretion of provider.

¹⁻ Hep B: If cAb+ & HBV DNA detected pre-treatment **OR** if Hep B carrier (sAg+) **OR** seroconverted carrier, check HBV DNA monthly during treatment & 3 months after treatment. If HBV DNA negative pre-treatment & not a carrier, check again only at end of treatment

²⁻ Child-Pugh Calculator: https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp
If score >6 (Child-Pugh B or C), do not treat with Mavyret™, Zepatier™, or Vosevi® and consult Liver Disease Specialist.

³⁻ If treatment includes ribavirin, additional monitoring of CBC, CMP is recommended at weeks 2, 4 and monthly throughout treatment and adjustment to ribavirin dose if GFR <50 or anemic. Consult Liver Disease specialist if patient is prescribed ribavirin.